Study group | Healthy controls | Allergic rhinitics | Asthmatics β2 | Asthmatics ICS | |||||
---|---|---|---|---|---|---|---|---|---|
Exposure | AIR | DE | AIR | DE | AIR | DE | AIR | DE | |
Pro-apoptotic markers | Bad | 10.8 (5.5 - 20.1) | 11.8 (9.1 - 23.3) | 29.8 (9.6 - 34.2) | 14.7 (4.0 - 27.4) | 12.4 (6.0 - 20.7) | 21.5 (4.3 - 41.4) | 14.4 (6.2 - 22.8) | 19.0 (10.7 - 28.8) |
Bak | 15.4 (3.8 - 36.4) | 17.2 (9.1 - 28.0) | 18.9 (8.8 - 31.7) | 26.4 (8.3 - 31.9) | 14.5 (10.3 - 33.7) | 27.0 (13.1 - 38.5) | 21.7 (13.3 - 33.2) | 23.8 (8.6 - 28.7) | |
Anti-apoptotic marker | Bcl-2 | 4.5 (0–11.4) | 0.06* (0.01 - 0.6) | 0.36 (0.19 - 1.2) | 0.07 (0–44.2) | 0.34 (0.02 - 5.1) | 2.8 (0–17.1) | 0.49 (0–3.3) | 0.08 (0–5.1) |
Death receptor | Fas | 2.8 (1.4 - 4.6) | 1.4 (0.4 - 5.5) | 1.8 (1.0 - 5.9) | 1.7 (0.3 - 10.8) | 1.9 (0.7 - 3.3) | 1.8 (0.4 - 3.0) | 1.3 (0.5 - 2.7) | 2.0 (0.5 - 1.2) |
Caspase cleavage product | P85 PARP | 1.7 (0.6 - 6.8) | 1.7 (1.0 - 2.8) | 3.8 (0.6 - 9.2) | 2.6 (0.8 - 6.0) | 2.2 (0.4 - 6.9) | 4.3 (1.1 - 7.2) | 2.1 (0.3- 4.6) | 2.6 (0.1 - 4.1) |
Proliferation marker | Ki67 | 1.9 (0.1 - 5.0) | 0.7 (0.3 - 3.6) | 1.7 (0.4 - 14.6) | 11.2 (1.5 - 34.1) | 3.1 (0.6 - 10.2) | 1.3 (0.2 - 3.4) | 1.2 (0.2 - 11.9) | 1.7 (0.9 - 8.0) |